Your Pakistan counterparty is one human being — Dr. Asif Masood Rana, trading as "Hivet Animal Health Business." Not a company. If Dr. Asif dies, retires, or has a dispute, the business has no legal continuity — JAPFA's receivables, DRAP registrations, and Pakistan market access dissolve into his personal estate. Pakistan Companies Act 2017 limited-liability protections do not apply. On top of that, the dispute clause names two arbitral institutions at once, LIBOR (the interest-rate reference) ceased to exist in June 2023 making the late-payment clause non-functional, the Pharmacovigilance Agreement is referenced three times but never attached, and HIVET has been sub-distributing to Azzalea apparently without JAPFA's prior written consent.
⚠️ Do not roll over the 2021 agreement into another renewal cycle without a substantial side-deed.The interest-rate clause uses LIBOR (Art. 8.3), which ceased to exist on 30 June 2023. The clause is non-functional — if JAPFA tried to invoke late-payment interest today, the formula produces zero rate. Distributor effectively gets free credit on late payments.
HIVET has been sub-distributing to Pakistan-Azzalea without (as far as the file shows) JAPFA's prior written consent under Art. 16.13. That sub-distribution agreement is now in active termination (16 Apr 2026). Send a reservation-of-rights letter to HIVET reaffirming Art. 16.13 was not waived for Azzalea before any Azzalea-side claim emerges.
Bottom line: Do not let this agreement renew or roll over without a substantial side-deed. The deal is operationally workable but legally fragile, and the sole-proprietorship counterparty is a single point of failure for the entire Pakistan market. If HIVET refuses to incorporate by next renewal (Dec 2026), pivot Pakistan distribution to UMEX (already a parallel JAPFA Pakistan counterparty).
Preamble describes HIVET as "a company incorporated under the laws of Pakistan" — but signature block describes Dr. Asif as "Proprietor" (sole proprietorship). The two are inconsistent.
Pakistan recognises sole proprietorship as an unregistered, non-juridical commercial form — the business and the man are legally one and the same. There is no limited-liability shield (the legal wall that normally protects company owners from business debts). If Dr. Asif dies, has incapacity, or gets divorced, the business has no legal continuity and JAPFA's receivables, DRAP registrations, and Pakistan market access enter probate. On the upside: his personal assets (house, car, savings) are accessible for enforcement.
"Arbitration in accordance with the Arbitration Rules of the Indonesian National Board of Arbitration (BANI) … the seat of arbitration shall be Singapore International Arbitration Centre ('SIAC Rules')."
The clause names two different institutions (BANI — the Indonesian arbitration institution in Jakarta — and SIAC — the Singapore arbitration institution) and two different rule books, and confuses "seat" (a city) with "institution" (SIAC). A tribunal asked to administer would face conflicting jurisdiction. Pakistan IS a NY Convention 1958 signatory (acceded 2005 — the global treaty making arbitration awards enforceable across borders), but a Pakistani court could find no enforceable arbitration agreement and assume jurisdiction itself.
Art. 22 termination triggers are silent on the 1266/1267 waiver.
KUHPerdata 1266 and 1267 are Indonesian Civil Code articles — under default Indonesian law, you cannot terminate a contract without going to court first; a one-line waiver clause fixes it. Without the waiver, even a textbook material breach by HIVET (missed Schedule A volumes, failed Art. 4.2 registration) forces JAPFA into a Jakarta district-court rescission action before termination is legally effective. Months of delay during which HIVET continues to operate under the contract.
Art. 1.12 defines a "Pharmacovigilance Agreement" between the parties. Art. 24.1 says PV activities "shall continue in accordance with the Pharmacovigilance Agreement." Art. 25 placeholder. No such side-agreement is attached or executed in the masterfile.
Pharmacovigilance (PV — the system of tracking and reporting bad reactions to a medicine after it's on the market) is mandatory under Pakistan DRAP (Drugs Act 1976 + Drugs Rules 1978) and under Indonesian Permentan 14/2017 (the regulation that says who is responsible for monitoring vaccine safety in Indonesia). Adverse-event reporting timeframes, signal-detection ownership, recall coordination — all currently undocumented. If a Vaksimune ND batch causes a flock-level adverse event in Pakistan tomorrow, liability allocation is open. Art. 12.7 says Distributor reports complaints "immediately" — "immediately" is litigable; market standard is 24-hour serious AE / 5-day non-serious AE.
No compliance representations of any kind. Art. 3.3 explicitly contemplates "open public tender invited by the government."
The contract is silent on anti-bribery (FCPA — the US anti-bribery law, UK Bribery Act, Indonesia Tipikor — the Indonesian anti-corruption law), sanctions screening (OFAC SDN — the US sanctions list, EU consolidated, UN), and data protection (UU PDP — the Indonesian data protection law). Pakistan is FATF-grey-list-adjacent (left list Oct 2022 but enhanced monitoring continues). Art. 3.3 explicitly contemplates "open public tender invited by the government" — direct FCPA exposure if any USD payment routes through US correspondent banks.
"Late payments by Distributor shall bear interest of rate LIBOR plus two point five percentage points (2.5%)…"
LIBOR (the London Interbank Offered Rate, the old global benchmark for floating interest rates) was discontinued globally on 30 June 2023. The clause is non-functional for any breach occurring post-June-2023. If JAPFA tried to invoke late-payment interest today, the clause produces zero rate — Distributor effectively gets free credit.
"Distributor shall surrender its usage rights to Supplier without any cost and shall further help Supplier in re-assigning such rights" — but no deadline, no penalty for delay.
HIVET could drag transfer of the DRAP marketing authorisation (the regulatory permit to sell the vaccine) for years, blocking JAPFA from appointing a successor distributor. UMEX is already a separate JAPFA Pakistan counterparty — but if HIVET refuses to release the registrations, UMEX cannot legally import the products.
Sub-distribution requires Supplier's prior written consent.
HIVET executed a "HIVET – AZZALEA Product Transfer Agreement" covering Vaksindo products, now in active termination (16 Apr 2026). There is no evidence in the masterfile that JAPFA gave prior written consent. This is a latent breach by HIVET — JAPFA has unused leverage. Defensive position: document NO Vaksindo consent was given before the Azzalea termination crystallises and Azzalea-side claims emerge.
| # | Issue | Negotiability | What to say in meeting |
|---|---|---|---|
| 1 | HIVET incorporation as Pte Ltd | Medium | "Both sides benefit from a corporate counterparty — bank KYC simpler, succession planning, your personal assets protected." |
| 2 | Fix Art. 33.2 dispute clause | High | "The clause is broken — it names two different arbitral institutions. Let's clean it up: SIAC Singapore + English + 3 arbitrators." |
| 3 | KUHPerdata 1266/1267 waiver | High | "One-line standard Indonesian-law clause. Both sides need this for clean termination." |
| 4 | Pharmacovigilance Agreement attached | High | "DRAP and Indonesian Permentan 14/2017 both require this. Let's get it on paper." |
| 5 | FCPA / sanctions / UU-PDP reps | High | "Standard compliance language — required by our banks." |
| 6 | LIBOR → Term SOFR | High | "LIBOR ceased in 2023. We need to update the rate reference." |
| 7 | MA transfer-back deadline (60 days + LD) | High | "Provides certainty for both sides on the exit path." |
| 8 | Bahasa Indonesia counterpart | High | "Indonesian law requires it — we'll handle translation." |
| 9 | Tiered discounts (0/2/4%) | Medium | "Rewards your growth and gives us predictable performance pull." |
| 10 | Azzalea consent reservation | High | (Defensive — reservation letter only, not a negotiation point.) |
Why 58/F: The strongest section is the Art. 4.2 bailee structure on MA ownership. The weakest are the sole-proprietorship counterparty form, the dual-headed dispute clause, the defunct LIBOR reference, the unattached Pharmacovigilance Agreement, and the missing compliance reps.
Post-side-deed projected score: If the 8 side-deed fixes land plus HIVET incorporates as Pte Ltd, score moves from 58/F → ~82/B.